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Drug-eluting stent (DES) therapy has represented a very significant milestone in the evolution of percutaneous coronary intervention (PCI) therapy. DES reduces the need of repeat intervention in the order of 35 -70% compare with bare metal stents. 1 However, there is still a need for research aimed at reducing restenosis since the need for re-intervention is not eliminated and certain anatomic and clinical scenarios, such as patients with diabetes mellitus, restenotic lesions after DES, bypass graft disease, and bifurcations, continue to be problematic for PCI therapy. 2, 3 To further reduce in-stent restenosis rates, research into improving stent and polymer design by testing and modifying drugs from various classes is necessary. To do this a relatively easy and cheap animal model is required. Animal models of diseases and related therapies serve two main purposes: first to increase the understanding of pathobiology and secondly to evaluate new therapies down to the histopathological level. Animal models have significantly advanced our understanding of the mechanisms of restenosis and have thereby improved the therapeutic options. For many years, the porcine model of stenting 4, 5 has been accepted as the most appropriate model, and more than 100 manuscripts assessing the anti-restenotic value of various agents in this model have been published. It has been the favoured model since porcine coronary anatomy, physiology, and pathophysiology closely mimic the situation in man. One major limitation of this model, however, is that 'normal' pigs are not susceptible to atherosclerosis, even when given a high-fat diet.
In this issue of Cardiovascular Research, Chamberlain et al.
6 present a new model of in situ stenting. Apolipoprotein E (ApoE)-and low-density lipoprotein receptor (LDL-R)-deficient mice are susceptible to atherosclerosis both with and without high-fat feeding. 7, 8 Consequently, a stenting model utilizing these mice has the potential of being a closer representation of the human situation. Moreover, mouse-specific reagents to analyse mechanisms in this model are widely available, which is in contrast to the difficulty in obtaining some pig-specific reagents.
One limiting factor that has slowed the establishment of a stent implantation model in mice is the small size of the murine arteries, which makes the procedure rather intricate. Ali et al. 9 have previously presented a murine model of stenting. In this model, aortic segments from either wild-type or ApoE knockout mice underwent balloon angioplasty and stenting with a 1.25 Â 2.5 mm stainless steel stent and were then subjected to carotidinterposition grafting into genetically identical littermates. This model is technically demanding, and although achievable by this group it may be difficult to transfer to other laboratories. Furthermore, it is not directly comparable to the situation in the clinic and it requires two mice for each procedure, which increases the cost of this approach. The new model presented by Chamberlain et al. 6 does not require an advanced level of micro-surgical skill and is directly comparable to the routine stent insertion used in the clinic. A selfexpanding coil stent made from nitinol wire was deployed using a catheter into the aorta of mice. Histological and immunohistochemical analysis of resin-embedded samples revealed a timedependent increase in neointima as previously observed with pig, rat, and rabbit models of restenosis. 5 As a proof of the utility of this model, Chamberlain et al. deployed stents into both wild-type and interleukin-1 receptor-deficient animals. As expected, neointima formation was decreased in interleukin-1 receptor-deficient mice, providing confidence in the model. There are many potential uses of this new model. First, it can be used to analyse cellular mechanisms in stented atherosclerotic mice. Secondly, it will be possible to use this approach in the numerous available transgenic and chimeric mice to assess the involvement of various target genes. This is clearly highlighted by the use of interleukin-1 receptor-deficient mice in this current study. 6 Thirdly, this model is amenable to pharmacological intervention studies at a fraction of the cost of the porcine model. One inherent limitation of this model and other stent models is difficult to analysing the restenotic tissue due to the presence of the metal stent struts. The metal struts hamper cutting of histological sections. Consequently, embedding the tissue in resin is necessary to enable cutting of histological sections. The down side of resin embedding is that it can hamper immunohistochemical analysis and specialized methods are required. Importantly, Chamberlain et al. 6 have devised a successful immunohistochemical analysis procedure using methylmethacrylate resin to detect smooth muscle, inflammatory, and endothelial cells. It is hoped that this method may be adaptable for determining expression of other target proteins in future studies. All models are a simplification of the real situation, and animal models are no exception. As with most animal models, this new mouse stent model is unlikely to simulate all the component processes of restenosis that occur in humans, and therefore it may not fully mimic the clinical problem. However, if the species-specific differences in arterial healing are considered in study design and interpretation, it will be of great use in the analysis of restenosis. One limitation of animal models of atherosclerosis is the composition and appearance of the atherosclerotic lesions that develop. Arteries of young animals, even those with hyperlipidaemic diets (containing lesions which develop during only a few weeks rather than decades in humans) do not show densely fibrous and acellular plaques with ulceration, calcification, thrombosis, or haemorrhage into the vessel wall, which are characteristic features of human restenotic lesions. However, maintaining mice on a high-fat diet for longer periods can aid the development of some of these characteristics, although this radically increases the cost of such studies. Moreover, it is also important to consider the difference in protective molecules against atherosclerosis in mouse models and humans. For example, cholesteryl ester transferase is present in humans but deficient in mice, and HDL levels are higher in mice than humans. 10 Furthermore, the fibrinolytic system in the mouse is very different to that in humans.
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In summary, these researchers should be commended for their establishment of this new model, which may be extensively used by various groups studying in-stent restenosis and may significantly enhance this area of research.
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